Relay Therapeutics, Inc. (RLAY)
NASDAQ: RLAY · Real-Time Price · USD
19.93
-0.14 (-0.70%)
Aug 13, 2026, 4:00 PM EDT - Market closed
Relay Therapeutics Revenue
Relay Therapeutics had revenue of $350.00K in the quarter ending June 30, 2026, a decrease of -48.30%. This brings the company's revenue in the last twelve months to $10.35M, up 23.86% year-over-year. In the year 2025, Relay Therapeutics had annual revenue of $15.36M with 53.44% growth.
Revenue (ttm)
$10.35M
Revenue Growth
+23.86%
P/S Ratio
421.98
Revenue / Employee
$51,238
Employees
202
Market Cap
4.37B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 15.36M | 5.35M | 53.44% |
| Dec 31, 2024 | 10.01M | -15.54M | -60.83% |
| Dec 31, 2023 | 25.55M | 24.17M | 1,749.82% |
| Dec 31, 2022 | 1.38M | -1.65M | -54.41% |
| Dec 31, 2021 | 3.03M | -79.63M | -96.34% |
| Dec 31, 2020 | 82.65M | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Legend Biotech | 1.27B |
| ACADIA Pharmaceuticals | 1.14B |
| Telix Pharmaceuticals | 803.79M |
| Tango Therapeutics | 53.81M |
| Denali Therapeutics | 3.60M |
RLAY News
- 3 days ago - Relay Therapeutics price target raised to $25 from $21 at BofA - TheFly
- 3 days ago - Relay Therapeutics price target raised to $26 from $21 at Citizens - TheFly
- 6 days ago - Relay Therapeutics price target raised to $30 from $27 at Barclays - TheFly
- 7 days ago - Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates - GlobeNewsWire
- 7 days ago - Relay Therapeutics Earnings release: Q2 2026 - Filings
- 7 days ago - Relay Therapeutics Quarterly report: Q2 2026 - Filings
- 14 days ago - Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026 - GlobeNewsWire
- 23 days ago - Relay Therapeutics price target raised to $31 from $22 at Goldman Sachs - TheFly